Navigation Links
Valensa Completes Second Expansion of Astaxanthin Capacity

"Made in USA" label and allergen-free status of extracted product driving demand

ORLANDO, Fla., April 14 /PRNewswire/ -- Valensa International announced that it has completed a second round of expansion for astaxanthin production at its Eustis, Florida facility. The move was made in light of growing demand for a high-quality astaxanthin from North America that is both pesticide-free and allergen-free -- two conditions that are only possible with carefully controlled raw material monitoring and extraction facilities that are not used for extractions of materials that are known to cause allergic reactions, such as legumes and shellfish. The company announced a 20% expansion of capacity in February 2008. With the new capacity, Valensa is now producing 40% more of its ZANTHIN(R) natural astaxanthin extract than it did in 2007.

According to Dr. Rudi E. Moerck, President and CEO of Valensa, the recent expansions have come as a result of rapidly increasing demand in Europe for astaxanthin for eye health formulations, but have also been fueled by European and U.S.-based companies needing to establish a clear country of origin for their astaxanthin products as well as assuage concerns about potential contamination by allergenic materials. "Right now, Valensa International is the only company in the market who manufactures -- or extracts -- astaxanthin oleoresin in the United States. As a fully integrated supplier of astaxanthin, our customers can rely on where their product gets made," Moerck said. "When marketers of natural astaxanthin contract out for the extraction of biomass to produce natural astaxanthin, there is a chance that the extracting company will process multiple raw materials through the same facilities. We have seen instances in the market where materials such as shellfish are produced in the same facilities as astaxanthin and are sold without appropriate label warnings introducing the possibility of allergenicity into the final astaxanthin extract. Companies who work with Valensa are assured that cross-contamination of this type does not exist, and as a result, have chosen a fully integrated solution from sourcing algae biomass, to CO2 extraction and standardization," he added.

Made in the USA

Valensa's ZANTHIN(R) natural astaxanthin is an ultra-high pressure supercritical CO2 extraction of Haematococcus pluvialis freshwater algae that uses no chemical solvents. Valensa is the only fully integrated supplier of natural astaxanthin extract in the U.S. It is made to cGMP standards in a certified organic facility in Florida and the product is protected with Valensa's all-natural, proprietary O2B(R) stabilization technology which provides extra stability in storage, efficacy and in customer's formulations. Valensa's approach to manufacturing ensures the highest-quality, most consistent product on the market -- and recommends it for eye health and for its potent anti-oxidant properties.

"Quality is critical to the acceptance of astaxanthin in all product formulations especially eye health formulas. At Valensa, we are committed to providing the highest-quality astaxanthin on the market," said Moerck.

    For further information, contact:

    Dr. Rudi Moerck, President and CEO
    Voice: 352-357-2004 ext. 701
    Fax: 352-483-2095

This release was issued through eReleases(TM). For more information, visit

SOURCE Valensa International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valensa Internationals Dr. Rudi E. Moerck Appointed CEO
2. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
3. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
4. Pacer Health Corporation Successfully Completes Assignment of $11.7 Million in Convertible Debentures
5. Metropolitan Nashville Hospital Authority Completes Voice and Data Upgrade with tw telecoms Network Solutions
6. Aegis Living Completes Purchase of Real Estate in Aptos
7. AMICAS Successfully Completes Tender Offer for Shares of Emageon Inc.
8. DST Systems, Inc. Completes Acquisition of Remaining 50% of Argus Health Systems, Inc.
9. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
10. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
11. Immunotech Completes Merger Acquisition
Post Your Comments:
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: